# Agibot

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agibot

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.agibot.net
- Total disclosed funding: $239M
- Investors on record: 9

## About

Established in 2020 and based in Suzhou, China, Agile Medical Technology (Suzhou) Co., Ltd., trading as Agibot, operates as a medical company that focuses on the development and production of surgical robots. It has branch offices and production bases in Shanghai and Suzhou. The company's R&D team consists of experts in the fields of medicine, mechanics, optics, electronics, algorithms, and software. Qun Zhao, the director of the company, is also a partner in the Healthcare field of Oriza Origin, with 14 years of experience in pharmaceutical company management. The company has 124 patents. In June 2022, its independently developed Agibot laparoscopic surgical robot completed the first animal experiment. In November 2025, Agibot closed a series B funding from new investors Elikon Venture, Nantong Investment Management, Oriza FoFs and Mingxi Capital. With participation from returning investors Oriza Holdings and Cenova Ventures.


The company focuses on the development of surgical robots for the precise diagnosis and treatment of benign and malignant diseases in multiple systems of the human body. It provides intelligent surgical solutions for clinical patients. Products include laparoscopic surgical robots, natural cavity surgical robots, etc. The AGIBOT laparoscopic surgical robot has successfully carried out registered clinical trials.

The company generates revenue by providing surgical robots.

The company plans to use the series B funding to accelerate technology research and development and industrialization, further expanding the breadth and depth of its clinical applications.

## Funding rounds

- Round, Oct 28, 2026, $225M
- Series B, Nov 3, 2025 — Oriza Holdings, Cenova Ventures, Nantong Investment Management, Oriza FoFs, Elikon Venture, Mingxi Capital
- Series A, Jul 1, 2024, $14M — Oriza Holdings, Cenova Ventures, Sherpa Healthcare Partners, Hengdian Capital Management, Yihe Private Equity Fund Management

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A, Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- Hengdian Capital Management — Series A
- Yihe Private Equity Fund Management (https://capitalatlas.ai/funds/yihe-private-equity-fund-management) — Series A
- Nantong Investment Management — Series B
- Oriza FoFs (https://capitalatlas.ai/funds/oriza-fofs) — Series B
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series B
- Mingxi Capital (https://capitalatlas.ai/funds/mingxi-capital) — Series B